10.31
-0.34 (-3.19%)
| Penutupan Terdahulu | 10.65 |
| Buka | 10.61 |
| Jumlah Dagangan | 2,853,420 |
| Purata Dagangan (3B) | 2,439,559 |
| Modal Pasaran | 1,279,172,096 |
| Harga / Pendapatan (P/E TTM) | 51.55 |
| Harga / Pendapatan (P/E Ke hadapan) | 33.56 |
| Harga / Jualan (P/S) | 5.65 |
| Harga / Buku (P/B) | 2.41 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 - 12 May 2025 |
| Margin Keuntungan | 9.85% |
| Margin Operasi (TTM) | 0.80% |
| EPS Cair (TTM) | 0.200 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 29.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 3,119.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 42.63% |
| Nisbah Semasa (MRQ) | 10.80 |
| Aliran Tunai Operasi (OCF TTM) | 66.51 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 49.10 M |
| Pulangan Atas Aset (ROA TTM) | 0.06% |
| Pulangan Atas Ekuiti (ROE TTM) | 4.48% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Dynavax Technologies Corporatio | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -4.0 |
| Purata | 0.13 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.54% |
| % Dimiliki oleh Institusi | 108.75% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Citizens Capital Markets, 220.08%) | Beli |
| Median | 31.00 (200.68%) | |
| Rendah | 10.00 (Goldman Sachs, -3.01%) | Jual |
| Purata | 26.25 (154.61%) | |
| Jumlah | 3 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 12.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 07 May 2025 | 31.00 (200.68%) | Beli | 11.48 |
| Goldman Sachs | 17 Apr 2025 | 10.00 (-3.01%) | Jual | 10.31 |
| 11 Feb 2025 | 12.00 (16.39%) | Jual | 12.70 | |
| Citizens Capital Markets | 21 Feb 2025 | 33.00 (220.08%) | Beli | 13.33 |
| HC Wainwright & Co. | 21 Feb 2025 | 31.00 (200.68%) | Beli | 13.33 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |